Yahoo Web Search

Search results

1. • ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International...

     Benzinga· 1 day ago

     Mr. Glover welcomes one-on-one meetings to discuss ZyVersa's technology, pipeline assets, and key development milestones. WESTON, Fla., May 14, 2024 (GLOBE...ZyVersa Therapeutics ...

2. • ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

     Digital Journal· 19 hours ago

     Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024CAMBRIDGE, Massachusetts ...

3. • 

     Sizing Up a Micro-Cap Biotech for a Speculative Play

     TheStreet.com· 2 days ago

     On Monday morning, AC Immune SA (ACIU) released its first-quarter financial results. Just who is ACIU? The Lausanne, Switzerland-headquartered clinical-...

4. • Seelos Therapeutics Announces 1-for-8 Reverse Stock Split

     FOX 59 Indianapolis· 23 hours ago

     (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare ...

5. • Coya Therapeutics Reports First Quarter 2024 Financial Results

     Guru Focus· 5 days ago

     The Houston-based clinical-stage biotechnology company reported a net loss of $5.1 million, which did not align with analyst expectations of a $4.43 million loss. Coya Therapeutics ...

6. • 

     ‘Sandwich generation’: How Raleigh family built an ADU for aging parents in their yard

     Raleigh News and Observer via AOL· 4 days ago

     The Millhausers, meanwhile, are settling into their new lives. Both have signed up for continuing...

7. • 

     ‘Sandwich generation’: How Raleigh family built an ADU for aging parents in their yard

     Raleigh News and Observer via Yahoo News· 4 days ago

     The Millhausers, meanwhile, are settling into their new lives. Both have signed up for continuing...

8. • ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ...

     GuruFocus.com via Yahoo Finance· 6 days ago

     ACADIA Pharmaceuticals showcases a 74% revenue surge and strategic expansions in its Q1 2024 earnings, underlining strong sales and future market plans.

9. • Mount Sinai Study Identifies Genetic Link Between | Newswise

     Newswise· 2 days ago

     Researchers at the Icahn School of Medicine at Mount Sinai have made a significant discovery, identifying genetic connections between inflammatory bowel disease (IBD) and ...

10. • NeuroSense Therapeutics (NASDAQ:NRSN) vs. Phathom Pharmaceuticals (NASDAQ:PHAT) Head-To-Head...

      ETF DAILY NEWS· 7 days ago

      NeuroSense Therapeutics (NASDAQ:NRSN – Get Free Report) and Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) are both small-cap medical companies, but which is the superior investment ...